ICGC Breast Cancer Project: Triple Negative/Lobular/Other
United Kingdom (UK)
1 April 2020 - 31 March 2021
Research collaboration: ICGC Breast Cancer Project: Triple Negative/Lobular/Other is a research collaboration whose article contributions are accrued to its participating partner institutions.
ICGC Breast Cancer Project: Triple Negative/Lobular/Other
Partner Institutions
ICGC Breast Cancer Project: Triple Negative/Lobular/Other is a research collaboration whose article contributions are accrued to its participating partner institutions below.
- The University of Queensland (UQ), Australia
- BC Cancer Agency (BCCA), PHSA, Canada
- Curie Institute, France
- French National Cancer Institute (INCa), France
- IRCCS National Cancer Institute (INT) Bari, Italy
- Erasmus University Rotterdam (EUR), Netherlands
- Academic Medical Center (AMC), UvA, Netherlands
- Radboud University Nijmegen (RU), Netherlands
- Oslo University Hospital (OUS), Norway
- University of Tromsø - The Arctic University of Norway (UiT), Norway
- Singapore General Hospital (SGH), Singapore
- Lund University (LU), Sweden
- King's College London (KCL), United Kingdom (UK)
- Cancer Research UK (CRUK), United Kingdom (UK)
- The Institute of Cancer Research (ICR), United Kingdom (UK)
- Wellcome Sanger Institute, United Kingdom (UK)
- Dana-Farber Cancer Institute (DFCI), United States of America (USA)
- International Cancer Genome Consortium (ICGC), Canada
